{"filings":[{"id":442726,"accession_number":"0001837607-26-000043","cik":1837607,"company_name":"AEON Biopharma, Inc.","ticker":"AEON","form_type":"8-K","filed_at":"2026-05-14T20:10:16+00:00","items":["7.01","9.01"],"status":"ready","headline":"AEON Biopharma posts corporate presentation targeting $3.5B neurotoxin market","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Corporate presentation made available on IR website, dated May 2026.","Presentation states AEON aims to disrupt a $3.5B neurotoxin market dominated by a single brand for over 30 years.","No specific financial results, clinical updates, or guidance changes disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":19354214.88746667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":442603,"accession_number":"0001837607-26-000041","cik":1837607,"company_name":"AEON Biopharma, Inc.","ticker":"AEON","form_type":"8-K","filed_at":"2026-05-14T20:06:45+00:00","items":["2.02","9.01"],"status":"ready","headline":"AEON Biopharma reports Q1 cash $6.2M; FDA supports ABP-450 biosimilar plan; debt cut >90%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA BPD Type 2a meeting deemed AEON's analytical similarity strategy reasonable for 351(k) pathway.","Completed $6M PIPE financing and Daewoong note exchange, reducing outstanding debt by >90%.","Appointed John Bencich as CFO, bringing 25+ years of corporate and capital markets experience.","Cash and cash equivalents $6.2M at March 31, plus $0.9M April ATM; funds operations into Q3 2026.","Plans BPD Type 2b meeting in H2 2026 to discuss remaining biosimilar development program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":19354214.88746667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96051,"accession_number":"0001837607-26-000025","cik":1837607,"company_name":"AEON Biopharma, Inc.","ticker":"AEON","form_type":"8-K","filed_at":"2026-04-03T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"AEON Biopharma gets second NYSE American delisting notice over $55M equity deficit","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["March 31, 2026 notice: not compliant with Section 1003(a)(ii) requiring ≥$4M stockholders' equity.","Stockholders' deficit ~$55M as of Dec 31, 2025; losses in 3 of last 4 fiscal years.","Prior non-compliance (Section 1003(a)(i)) from Feb 2025; NYSE American accepted compliance plan through Aug 3, 2026.","Stock continues trading under AEON with '.BC' indicator; company remains on noncompliant issuers list.","Failure to regain compliance by Aug 3, 2026 could lead to delisting; business operations unaffected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":19354214.88746667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109593,"accession_number":"0001837607-26-000018","cik":1837607,"company_name":"AEON Biopharma, Inc.","ticker":"AEON","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AEON Biopharma reports positive biosimilarity data for ABP-450, raises $6M PIPE, reduces debt 90%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial analytical results confirm 100% amino-acid sequence match to BOTOX and highly similar functional characteristics.","FDA BPD Type 2a meeting provided clear framework for remaining analytical comparability program; majority to be completed in 2026.","Completed $6M PIPE financing and Daewoong note exchange, reducing outstanding debt by more than 90%.","Appointed John Bencich as CFO; cash of $3.0M at Dec 31, 2025 plus $4.2M Jan PIPE proceeds expected to fund ops into Q3 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":19354214.88746667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109592,"accession_number":"0001837607-26-000009","cik":1837607,"company_name":"AEON Biopharma, Inc.","ticker":"AEON","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"AEON Biopharma appoints John Bencich as CFO, amends inducement plan by 1M shares","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Bencich appointed CFO effective March 9, 2026; base salary $450k, bonus target 40%.","Equity grants: 754,717 RSUs (4-year vest) and 235,849 PSUs tied to NYSE American compliance.","Jennifer Sy enters CAO employment agreement with $275k base, 30% bonus target, and severance terms.","Board adds 1,000,000 shares to 2025 Inducement Plan for equity awards without stockholder approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":19354214.88746667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109591,"accession_number":"0001837607-26-000005","cik":1837607,"company_name":"AEON Biopharma, Inc.","ticker":"AEON","form_type":"8-K","filed_at":"2026-01-21T23:59:59+00:00","items":["3.02","5.02","5.07","7.01","8.01","9.01"],"status":"ready","headline":"AEON shareholders approve PIPE/Daewoong exchange; BPD Type 2a meeting held with FDA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved PIPE financing, Daewoong note exchange, and 2023 incentive plan at special meeting; exchange closed Jan 21.","Daewoong exchanged $15M senior secured notes for 11.9M shares, 11.2M pre-funded warrants, $1.5M new note, and 8M warrants.","Second closing of PIPE expected week of Jan 26: 4.6M shares, 6.6M warrants, and up to 6.6M true-up warrants.","AEON held BPD Type 2a meeting with FDA for ABP-450 biosimilar; awaiting official minutes within ~30 days.","Fifth amendment to license agreement with Daewoong adjusts termination purchase right based on Daewoong's sale of 50% of its shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":19354214.88746667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109590,"accession_number":"0001837607-26-000002","cik":1837607,"company_name":"AEON Biopharma, Inc.","ticker":"AEON","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AEON Biopharma issues corporate presentation with no new material facts","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation dated January 2026 made available on IR website (Item 7.01).","Reiterates ABP-450 as biosimilar to BOTOX, aiming to be first complete therapeutic alternative.","No financial or clinical data disclosed; no guidance or milestones provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":19354214.88746667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126119,"accession_number":"0001837607-25-000092","cik":1837607,"company_name":"AEON Biopharma, Inc.","ticker":"AEON","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"AEON Biopharma signs definitive exchange with Daewoong; $15M notes swapped for equity, new $1.5M note due 2030","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exchange eliminates >90% of AEON's outstanding debt; Daewoong receives ~23.1M shares, $1.5M new convertible note at 15.79% due Apr 2030.","Daewoong gets cash-exercise warrant for 8M shares at $1.09392/share, representing up to $8M+ potential proceeds for AEON.","Exchange remains subject to stockholder vote; closing expected after vote on Jan 21, 2026.","Daewoong will nominate Seongsoo Park as Class III director at 2026 annual meeting; Park currently on board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":19354214.88746667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126118,"accession_number":"0001837607-25-000088","cik":1837607,"company_name":"AEON Biopharma, Inc.","ticker":"AEON","form_type":"8-K","filed_at":"2025-12-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AEON Biopharma posts corporate presentation with biosimilar pipeline update","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation dated December 2025 highlights fresh data and new capital for full-label biosimilar approval.","Company emphasizes simplified structure to accelerate development of lead molecule.","No specific clinical or financial figures were disclosed in the furnished presentation excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":19354214.88746667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126117,"accession_number":"0001837607-25-000084","cik":1837607,"company_name":"AEON Biopharma, Inc.","ticker":"AEON","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AEON Biopharma reports positive ABP-450 biosimilarity data, secures $6M PIPE and debt reduction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ABP-450 shows 100% amino-acid sequence identity to BOTOX (93-99% coverage across five proteins) and highly similar functional characteristics.","FDA Type 2a meeting scheduled for November 19, 2025 to review analytical package ahead of biosimilar pathway.","$6M PIPE and Daewoong note exchange expected to reduce outstanding debt by over 90% and extend cash runway into Q2 2026.","Cash and equivalents $5.9M as of Sep 30, 2025; combined financing expected to fund operations through Q2 2026.","ABP-450 has global approval in 69 countries, supporting fully scaled manufacturing platform."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":19354214.88746667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126116,"accession_number":"0001837607-25-000072","cik":1837607,"company_name":"AEON Biopharma, Inc.","ticker":"AEON","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"AEON Biopharma raises $6M private placement, plans Daewoong note exchange for ~23M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First closing of private placement expected week of Nov 17, 2025: 1,964,905 shares/pre-funded warrants at $0.9116 per share.","Second closing subject to stockholder approval: 4,616,924 shares and 6,581,829 warrants at $1.09392.","Term sheet with Daewoong to exchange existing notes for $1.5M new note, ~23.1M shares, and 8M warrants.","True-Up Warrants issued to maintain investor ownership percentage post-Daewoong exchange.","Investors receive registration rights for resale of shares and warrant shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":19354214.88746667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142848,"accession_number":"0001837607-25-000068","cik":1837607,"company_name":"AEON Biopharma, Inc.","ticker":"AEON","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AEON Biopharma makes corporate presentation available; limited specifics disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation references $3B+ U.S. neurotoxin therapeutic market via biosimilarity approach.","No financial guidance, pipeline updates, or milestones provided in filing or excerpt.","CEO Robert Bancroft signs 8-K; presentation may be used in future investor meetings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":19354214.88746667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142847,"accession_number":"0001837607-25-000065","cik":1837607,"company_name":"AEON Biopharma, Inc.","ticker":"AEON","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AEON Biopharma reports Q2 2025 cash of $8.4M; advancing ABP-450 biosimilar milestones","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Cash and equivalents $8.4M as of June 30, 2025; expected to fund operations through Q4 2025 and Type 2a FDA meeting.","Primary structure and select functional analyses for ABP-450 expected to complete in Q3 2025.","Type 2a meeting with FDA on 351(k) biosimilar pathway anticipated in Q4 2025.","Pursuing ABP-450 as BOTOX biosimilar for all therapeutic indications; over $3B U.S. therapeutic market opportunity noted."],"consensus_eps_estimate":null,"consensus_eps_actual":0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":19354214.88746667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160932,"accession_number":"0001837607-25-000059","cik":1837607,"company_name":"AEON Biopharma, Inc.","ticker":"AEON","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"AEON Biopharma elects Fischer and Carter as Class II directors; ratifies KPMG","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Jost Fischer and Eric Carter elected as Class II directors for three-year terms ending 2028.","Fischer received 661,774 votes for and 138,295 withheld; Carter 674,894 for and 125,175 withheld.","KPMG ratified as independent auditor for FY 2025 with 4,956,438 for, 170,672 against, 30,177 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":19354214.88746667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160931,"accession_number":"0001837607-25-000055","cik":1837607,"company_name":"AEON Biopharma, Inc.","ticker":"AEON","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AEON Biopharma presents corporate update at Aegis Capital Conference, focusing on PrabotulinumtoxinA","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Presentation highlights PrabotulinumtoxinA as a therapeutic botulinum toxin product candidate.","Corporate presentation made available on AEON's investor relations website on May 20, 2025.","No specific clinical data, financial results, or material changes disclosed in the furnished slides."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":19354214.88746667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160930,"accession_number":"0001837607-25-000049","cik":1837607,"company_name":"AEON Biopharma, Inc.","ticker":"AEON","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AEON Biopharma appoints new CEO, advances ABP-450 biosimilar path, reports $10.4M cash","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Rob Bancroft appointed President and CEO effective April 29, 2025; also joins Board. Former CEO Marc Forth remains on Board.","Pursuing 351(k) biosimilar pathway for ABP-450 with BOTOX as reference; plans BPD Type 2a meeting with FDA in H2 2025.","Cash and equivalents of $10.4M at March 31, 2025; expected to fund operations through Q4 2025 and planned FDA meeting.","NYSE American accepted compliance plan; granted until August 3, 2026 to regain continued listing standards."],"consensus_eps_estimate":null,"consensus_eps_actual":2.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":19354214.88746667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160929,"accession_number":"0001837607-25-000032","cik":1837607,"company_name":"AEON Biopharma, Inc.","ticker":"AEON","form_type":"8-K","filed_at":"2025-04-25T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"NYSE American accepts AEON's compliance plan; delisting risk deferred to Aug 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NYSE American accepted AEON's compliance plan on April 22, 2025, granting until August 3, 2026 to meet listing standards under Sections 1003(a)(i)-(iii).","AEON remains listed on NYSE American under symbol AEON during the Plan Period, subject to periodic progress reviews.","Failure to regain compliance or make sufficient progress by August 3, 2026 may lead to delisting proceedings.","Non-compliance was first disclosed in February 2025; plan submission deadline was March 5, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":19354214.88746667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160928,"accession_number":"0001837607-25-000030","cik":1837607,"company_name":"AEON Biopharma, Inc.","ticker":"AEON","form_type":"8-K","filed_at":"2025-04-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"AEON Biopharma appoints Robert Bancroft as CEO effective April 29; Jost Fisher remains chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bancroft appointed PEO, President, CEO and Class I director effective April 29, 2025.","Jost Fisher steps down as Interim CEO but continues as chairman and on audit/comp committees.","Bancroft base salary $425k, eligible for annual bonus target 50% of salary.","Bancroft receives 59,034 stock options and 177,103 RSUs under new Inducement Plan (1M shares reserved).","Prior role: GM of Therapeutics at Revance Therapeutics until its acquisition by Crown Labs in Feb 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":19354214.88746667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160927,"accession_number":"0001837607-25-000027","cik":1837607,"company_name":"AEON Biopharma, Inc.","ticker":"AEON","form_type":"8-K","filed_at":"2025-04-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"AEON Biopharma appoints Jost Fischer Interim CEO and Jennifer Sy as principal financial officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["On April 3, 2025, Board formally appointed Jost Fischer as Interim President, CEO and principal executive officer, effective April 4, 2025.","Board appointed Jennifer Sy as Chief Accounting Officer and principal financial officer, effective April 4, 2025.","Ms. Sy previously served as VP, Corporate Controller since August 2023; base salary increased to $275,000 from $245,000.","Mr. Fischer continues as Chairman of the Board; no other compensation changes disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":19354214.88746667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179137,"accession_number":"0001837607-25-000025","cik":1837607,"company_name":"AEON Biopharma, Inc.","ticker":"AEON","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"AEON CEO Marc Forth resigns; Chairman Jost Fischer named interim CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Marc Forth steps down as President and CEO effective April 4, 2025, to pursue another opportunity.","Forth remains on the board; departure is not due to any disagreement with AEON.","Chairman Jost Fischer appointed Interim CEO; board actively seeking permanent replacement.","AEON expects current cash to fund through Biosimilar BPD Type 2a meeting with FDA in H2 2025.","AEON is a clinical-stage biopharma developing botulinum toxin complex ABP-450 as a BOTOX biosimilar."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":19354214.88746667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179136,"accession_number":"0001837607-25-000021","cik":1837607,"company_name":"AEON Biopharma, Inc.","ticker":"AEON","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AEON Biopharma advances ABP-450 biosimilar program, secures $20M funding","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Pursuing 351(k) biosimilar pathway for ABP-450 with BOTOX as reference product for all therapeutic indications.","Initiated primary analytical studies in Q4 2024; plans BPD Type 2a meeting with FDA in H2 2025.","Closed $20M public offering in Jan 2025; ~89% of Series B warrants exercised as of March 21, 2025.","No specific FY2024 financial results disclosed in the press release; focus on development and funding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":19354214.88746667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179135,"accession_number":"0001837607-25-000015","cik":1837607,"company_name":"AEON Biopharma, Inc.","ticker":"AEON","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AEON Biopharma posts corporate presentation; details limited","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation made available on IR website on March 10, 2025.","Focus on PrabotulinumtoxinA as a potential biosimilar for therapeutic indications.","No specific financial, clinical, or operational data disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":19354214.88746667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179134,"accession_number":"0001837607-25-000013","cik":1837607,"company_name":"AEON Biopharma, Inc.","ticker":"AEON","form_type":"8-K","filed_at":"2025-02-24T23:59:59+00:00","items":["3.03","5.03","5.07","7.01","9.01"],"status":"ready","headline":"AEON Biopharma approves 1-for-72 reverse stock split to maintain NYSE American listing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio of 1-for-72; effective 12:01 AM ET on February 26, 2025.","Outstanding shares reduced from ~79.9 million to ~1.1 million; fractional shares rounded up.","Authorized shares increased from 500 million to 1.04 billion at special meeting.","Ticker 'AEON' unchanged; new CUSIP 00791X 209; votes: 32.6M for, 3.6M against.","Purpose: increase share price to comply with NYSE American continued listing standards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":19354214.88746667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179133,"accession_number":"0001837607-25-000010","cik":1837607,"company_name":"AEON Biopharma, Inc.","ticker":"AEON","form_type":"8-K","filed_at":"2025-02-07T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"AEON Biopharma receives NYSE American delisting notice over stockholder deficit of $32.1M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received notice on Feb 3, 2025 for non-compliance with Section 1003(a)(i) requiring $2M+ stockholders' equity.","Reported stockholders' deficit of $32.1M as of Sept 30, 2024 and losses in two of the three most recent fiscal years.","Must submit a compliance plan by March 5, 2025; has until Aug 3, 2026 to regain compliance.","If plan not accepted or fails, delisting proceedings will commence; shares will trade with \".BC\" designation.","No immediate impact on listing or business operations; company intends to submit a plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":19354214.88746667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179132,"accession_number":"0001104659-25-001665","cik":1837607,"company_name":"AEON Biopharma, Inc.","ticker":"AEON","form_type":"8-K","filed_at":"2025-01-07T23:59:59+00:00","items":["1.01","8.01"],"status":"ready","headline":"AEON Biopharma closes $20M public offering; net proceeds ~$18.3M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$20M from 40M common units at $0.50/unit (1 share + 1 Series A + 1 Series B warrant).","Net proceeds after underwriting fees ~$18.3M; over-allotment added 6M Series A and 6M Series B warrants.","Funds expected to support operations through 2025 and advance ABP-450 biosimilar development.","After offering, shares outstanding ~79.97M; warrants exercisable at $0.625/share post-stockholder approval.","CEO Marc Forth highlighted sufficient capital for 351(k) regulatory pathway and planned BPD Type 2 meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":19354214.88746667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179131,"accession_number":"0001104659-25-001109","cik":1837607,"company_name":"AEON Biopharma, Inc.","ticker":"AEON","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"AEON Biopharma prices $20M public offering of units and warrants to fund operations through 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$20M from 40M units at $0.50/unit; each unit includes one share or Pre-Funded Warrant plus two Series A and B Warrants at $0.625 exercise.","Series A Warrants exercisable after stockholder approval, expire 60 months; Series B Warrants exercisable after approval, expire 30 months with cashless option.","Aegis Capital Corp. sole book-runner; underwriter has 45-day option to purchase up to 15% additional shares/warrants for over-allotments.","Expected close Jan 7, 2025; net proceeds for general corporate purposes and development of ABP-450 botulinum toxin biosimilar.","CEO Marc Forth: capital sufficient through 2025; plans BPD Type 2 meeting with FDA in 2025 to discuss next steps."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":19354214.88746667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195801,"accession_number":"0001104659-24-130805","cik":1837607,"company_name":"AEON Biopharma, Inc.","ticker":"AEON","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Aeon Biopharma reduces shareholder quorum requirement to 33.34%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Quorum for shareholder meetings changed from a majority to 33.34% of outstanding voting power.","Amendment to Bylaws adopted on December 18, 2024, effective immediately.","Certificate of Amendment filed as Exhibit 3.1 with the SEC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":19354214.88746667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195800,"accession_number":"0001837607-24-000092","cik":1837607,"company_name":"AEON Biopharma, Inc.","ticker":"AEON","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AEON Biopharma Q3 2024: FDA aligned on biosimilar path for ABP-450, but capital constraints persist","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Held Biosimilar Initial Advisory meeting with FDA in Q3; aligned on 351(k) pathway using BOTOX as reference.","Primary comparative analytical studies planned for Q4 2024, subject to securing capital resources.","BPD Type 2 meeting with FDA targeted in 2025 to discuss study outcomes.","CEO cites capital resources as single biggest limitation; evaluating all options to fund regulatory strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":19354214.88746667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195799,"accession_number":"0001837607-24-000085","cik":1837607,"company_name":"AEON Biopharma, Inc.","ticker":"AEON","form_type":"8-K","filed_at":"2024-10-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AEON Biopharma posts new corporate presentation highlighting prabotulinumtoxinA biosimilar","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Corporate presentation posted on IR site on October 7, 2024, used for investor meetings.","Slide deck focuses on prabotulinumtoxinA as a potential biosimilar for therapeutic indications.","No financial results, guidance, or material corporate events disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":19354214.88746667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212079,"accession_number":"0001837607-24-000083","cik":1837607,"company_name":"AEON Biopharma, Inc.","ticker":"AEON","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AEON Biopharma plans biosimilar development of ABP-450 targeting BOTOX; FDA meeting set for Q3 2024","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["ABP-450 will be developed as a biosimilar using BOTOX as reference product under 351(k) pathway.","Biosimilar initial advisory meeting with FDA scheduled for Q3 2024.","Planned Phase 3 cervical dystonia study of ~400 patients to compare ABP-450 to BOTOX.","No specific financial results for Q2 2024 were disclosed in the press release.","Company notes development is subject to securing funding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":19354214.88746667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212078,"accession_number":"0001837607-24-000079","cik":1837607,"company_name":"AEON Biopharma, Inc.","ticker":"AEON","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AEON Biopharma posts new corporate presentation; no financial updates disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["New corporate presentation posted on August 6, 2024, highlighting PrabotulinumtoxinA as a biosimilar candidate.","The filing does not disclose any financial results, guidance, or clinical data updates.","No changes to business strategy or pipeline were announced in the 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":19354214.88746667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212077,"accession_number":"0001837607-24-000077","cik":1837607,"company_name":"AEON Biopharma, Inc.","ticker":"AEON","form_type":"8-K","filed_at":"2024-07-09T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"AEON Biopharma shifts ABP-450 to biosimilar pathway targeting BOTOX; plans pivotal study in cervical dystonia","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ABP-450 will pursue 351(k) biosimilar pathway using AbbVie's BOTOX as reference product.","Company plans a single pivotal Phase 3 comparative study in cervical dystonia.","Successful Phase 3 could support biosimilar determination for up to 8 therapeutic indications.","Biosimilar Initial Advisory Meeting with FDA scheduled for Q3 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":19354214.88746667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230933,"accession_number":"0001837607-24-000070","cik":1837607,"company_name":"AEON Biopharma, Inc.","ticker":"AEON","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"AEON Biopharma stockholders elect two Class I directors and approve potential Daewoong issuance at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Robert Palmisano and Shelley Thunen elected as Class I directors for three-year terms ending 2027.","Stockholders approved potential issuance of 20%+ of Class A common stock to Daewoong Pharmaceuticals at below-market value, a change-of-control measure.","Ratification of KPMG LLP as auditor for fiscal 2024 passed with 25,491,112 votes for.","All three proposals received sufficient votes; broker non-votes were 675,301 on first two proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":19354214.88746667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230932,"accession_number":"0001837607-24-000066","cik":1837607,"company_name":"AEON Biopharma, Inc.","ticker":"AEON","form_type":"8-K","filed_at":"2024-05-16T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"AEON Biopharma discontinues Phase 2 migraine study after failed endpoints; CFO terminated, CEO takes PFO role","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 double-blind migraine study (episodic and chronic cohorts) discontinued; chronic cohort failed primary and secondary endpoints.","Open-label extension study also stopped; patients monitored for safety for 12 weeks post last treatment.","CEO Marc Forth appointed principal financial officer after termination of CFO Peter Reynolds effective May 17, 2024.","Jennifer Sy appointed principal accounting officer; no additional compensation for Forth or Sy.","Company to conserve cash and evaluate strategic options after study discontinuation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":19354214.88746667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230931,"accession_number":"0001837607-24-000062","cik":1837607,"company_name":"AEON Biopharma, Inc.","ticker":"AEON","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AEON Biopharma Phase 2 chronic migraine study misses primary and secondary endpoints","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Phase 2 chronic migraine interim analysis did not achieve primary or secondary endpoints.","End-of-Phase 2 meeting with FDA for episodic migraine resulted in preliminary alignment on Phase 3 design.","Completed $15M private placement with Daewoong; second installment received April 2024.","Seongsoo (Shawn) Park appointed to Board of Directors as Daewoong's representative.","Company evaluating next-steps across late-stage clinical pipeline for ABP-450."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":19354214.88746667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230930,"accession_number":"0001837607-24-000047","cik":1837607,"company_name":"AEON Biopharma, Inc.","ticker":"AEON","form_type":"8-K","filed_at":"2024-05-03T23:59:59+00:00","items":["4.02"],"status":"ready","headline":"AEON Biopharma restates 2023 financials; non-cash error adds $348M loss; going concern doubt","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board concludes Q3 2023 and FY 2023 financials unreliable due to IPR&D write-off misclassification.","Non-cash correction increases reported loss by $348M; cash balances and operating cash flow unaffected.","Company plans to file restated audited FY 2023 financials and amend Q3 2023 10-Q.","Expects to disclose additional material weakness and substantial doubt about going concern for 12 months.","KPMG notified; error has no impact on prior cash or operating cash flow."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":19354214.88746667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230929,"accession_number":"0001104659-24-056664","cik":1837607,"company_name":"AEON Biopharma, Inc.","ticker":"AEON","form_type":"8-K","filed_at":"2024-05-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"AEON Biopharma Phase 2 trial of ABP-450 for chronic migraine fails primary endpoint","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint: mean reduction in monthly migraine days (MMD) at weeks 13-24 was 8.5 (150U), 7.7 (195U), 8.4 (placebo); p=0.9132 and 0.3611.","Trial did not achieve statistical significance for primary or any secondary endpoints; placebo response was unexpectedly higher than historical studies.","Company immediately commencing cash preservation measures and reviewing all strategic options for ABP-450 development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":19354214.88746667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}